



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/561,583
Filing Date	March 15, 2007
First Named Inventor	VAN WAMEL, WILLEM JAN BASTIAAN
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	ARSI-012

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Preliminary Amendment and Certification Regarding Sequence Listing (13 pgs.) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input checked="" type="checkbox"/> Drawing(s) 3 Sheets of Replacement Drawings 3 Sheets of (Marked Up) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input checked="" type="checkbox"/> Sequence Listing (Paper Copy) (10 pgs.) <input checked="" type="checkbox"/> CD, Number of CD(s) 1 <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Copy of Notification of Defective Response (2 pgs.) 2. Communication re Sub Spec (1 pg.) 3. Substitute Specification – Marked-Up Copy (56 pgs) 4. Substitute Specification – Clean Copy (61 pgs.) 5. Abstract (1pm) 6. Return Postcard
---	--	---

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	BOZICEVIC, FIELD & FRANCIS, LLP		
Signature			
Printed Name	CAROL L. FRANCIS, PH.D.		
Date	September 10, 2007	Reg. No.	36,513

EXPRESS MAIL LABEL NO. EV 955 153 796 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JFW



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
-----------------------------	-----------------------	------------------

10/561,583

Willem Jan Bastiaan Van Wamel

ARSI-012

INTERNATIONAL APPLICATION NO.

PCT/EP04/07606

I.A. FILING DATE

PRIORITY DATE

07/08/2004

24353

BOZICEVIC, FIELD & FRANCIS LLP
 1900 UNIVERSITY AVENUE
 SUITE 200
 EAST PALO ALTO, CA 94303

CONFIRMATION NO. 6152

371 FORMALITIES LETTER



OC000000025296714

Date Mailed: 08/10/2007

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Copy of the International Application filed on 12/19/2005
- Copy of the International Search Report filed on 12/19/2005
- Copy of IPE Report filed on 12/19/2005
- Preliminary Amendments filed on 03/15/2007
- Oath or Declaration filed on 03/15/2007
- U.S. Basic National Fees filed on 12/19/2005
- Priority Documents filed on 12/19/2005
- Power of Attorney filed on 03/15/2007
- Specification filed on 12/19/2005
- Claims filed on 12/19/2005
- Abstracts filed on 12/19/2005
- Drawings filed on 12/19/2005

RECEIVED

AUG 14 2007

Bozicevic, Field, & Francis

Applicant's response filed 03/15/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 01/24/2007 have not been completed.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821

- (e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

DEBORAH D WILLIAMS

Telephone: (703) 308-9140 EXT 205

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/561,583	PCT/EP04/07606	ARSI-012

EXPRESS MAIL LABEL NO. EV 955 153 796 US

<p align="center">COMMUNICATION REGARDING SUBSTITUTE SPECIFICATION</p> <p>Address to: Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p>	Attorney Docket No.	ARSI-012
	Confirmation No.	6152
	First Named Inventor	VAN WAMEL, WILLEM JAN BASTIAAN
	Application Number	10/561,583
	Filing Date	March 15, 2007
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
<p>Title: "THERAPEUTIC USE OF LPI, A STAPHYLOCOCCAL LECTIN PATHWAY INHIBITOR IN INFLAMMATORY DISEASES"</p>		

Sir:

Applicants provide herewith a Substitute Specification pursuant to 37 C.F.R. §1.125, excluding the claims and abstract.

Please replace pages 1-56 of the specification as filed with pages 1-61 of the Substitute Specification submitted herewith.

The amendments are to insert sequence identifiers to bring the application in conformance with the Sequence Listing requirements of 37 CFR §§ 1.821 – 1.825.

In addition to the clean copy of the substitute specification, a copy of the substitute specification with markings showing all the changes relative to the immediate prior version of the specification of record (labeled "Marked-Up Copy") accompanies this communication.

No new matter has been added.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number ARSI-012.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: Sept 10, 2007

By: Carol L. Francis
Carol L. Francis, Ph.D.
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231